Literature DB >> 17089886

JNK pathway as therapeutic target to prevent degeneration in the central nervous system.

Mariaelena Repici1, Tiziana Borsello.   

Abstract

JNKs (c-Jun N- terminal kinases) are important transducing enzymes involved in many faces of cellular regulation such as gene expression, cell proliferation and programmed cell death. The activation of JNK pathway is critical for naturally occurring neuronal death during development as well as for pathological death of adult brain following different insults. In particular, JNKs play an important role in excitotoxicity and all related phenomena. Initial research concentrated on defining the components and organization of JNK signalling cascades, but more recent studies have begun to see JNK as the appropriate target for prevent cell loss. We used a specific JNK inhibitor, the cell permeable peptide D-JNKI1, to block JNK action in neuronal death following excitotoxicity in vitro and cerebral ischemia in vivo. Here we review our recent findings and we discuss the possibility of using D-JNKI1 as a therapeutic agent to prevent cell loss in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089886     DOI: 10.1007/978-0-387-34817-9_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

2.  Inhibition of phosphorylation of JNK suppresses Aβ-induced ER stress and upregulates prosurvival mitochondrial proteins in rat hippocampus.

Authors:  Parvin Yenki; Fariba Khodagholi; Fatemeh Shaerzadeh
Journal:  J Mol Neurosci       Date:  2012-06-17       Impact factor: 3.444

3.  Delayed inhibition of c-Jun N-terminal kinase worsens outcomes after focal cerebral ischemia.

Authors:  Yoshihiro Murata; Norio Fujiwara; Ji Hae Seo; Feng Yan; Xiangrong Liu; Yasukazu Terasaki; Yumin Luo; Ken Arai; Xunming Ji; Eng H Lo
Journal:  J Neurosci       Date:  2012-06-13       Impact factor: 6.167

4.  Tumor necrosis factor-alpha-induced sickness behavior is impaired by central administration of an inhibitor of c-jun N-terminal kinase.

Authors:  K Palin; R H McCusker; K Strle; F Moos; R Dantzer; K W Kelley
Journal:  Psychopharmacology (Berl)       Date:  2008-02-12       Impact factor: 4.530

5.  A novel role for jun N-terminal kinase signaling in olfactory sensory neuronal death.

Authors:  Nidhi M Gangadhar; Stuart J Firestein; Brent R Stockwell
Journal:  Mol Cell Neurosci       Date:  2008-05-11       Impact factor: 4.314

6.  Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1.

Authors:  Saebyeol Jang; Keith W Kelley; Rodney W Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

7.  Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats.

Authors:  Zikra Zulfiqar; Fawad Ali Shah; Shagufta Shafique; Abdullah Alattar; Tahir Ali; Arooj Mohsin Alvi; Sajid Rashid; Shupeng Li
Journal:  J Inflamm Res       Date:  2020-12-24

8.  Anti-parkinsonian effects of octacosanol in 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-treated mice.

Authors:  Tao Wang; Yanyong Liu; Nan Yang; Chao Ji; Piu Chan; Pingping Zuo
Journal:  Neural Regen Res       Date:  2012-05-15       Impact factor: 5.135

9.  APP upregulation contributes to retinal ganglion cell degeneration via JNK3.

Authors:  Chao Liu; Cheng-Wu Zhang; Yi Zhou; Wan Qing Wong; Liying Corinne Lee; Wei Yi Ong; Sung Ok Yoon; Wanjin Hong; Xin-Yuan Fu; Tuck Wah Soong; Edward H Koo; Lawrence W Stanton; Kah-Leong Lim; Zhi-Cheng Xiao; Gavin S Dawe
Journal:  Cell Death Differ       Date:  2017-12-13       Impact factor: 15.828

10.  A p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of cellular p38 inhibition data.

Authors:  Roman Anton; Silke M Bauer; Peter R W E F Keck; Stefan Laufer; Ulrich Rothbauer
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.